Discover the emerging science in AD from experts in the field.
DUPIXENT was studied in adult patients with moderate-to-severe AD who were inadequately controlled by topical treatments or ciclosporin1
Discover the emerging science in AD from experts in the field.
Find out what additional resources are available to download to provide you with further information about DUPIXENT and support you in treating your patients with AD.
aged 12 years or older with moderate-to-severe AD have been prescribed DUPIXENT in the U.S.A and Europe as of December 20196
251 adolescent patients with moderate-to-severe AD that were inadequately controlled with topical treatments, participated in a study (AD-1526) to investigate the efficacy of DUPIXENT as a monotherapy for up to 16 weeks1
Gain access to watch past webinars, videos and narrated lectures on DUPIXENT
Targeted therapy towards IL-4 and IL-13, key drivers of persistent underlying Type 2 inflammation1,2
Safety has been investigated in patients for up to 52 weeks in adolescents and 3 years in adults1,9,10
Improvements in lesion extent and severity compared to placebo at 16 weeks in all populations and sustained in adults at 52 weeks1,7,8
DUPIXENT can be self-administered by subcutaneous injection by pre-filled syringe or pre-filled pen1
AD, atopic dermatitis; IL, interleukin; RWE, real-world evidence.
References